Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 3/15/2019 |
| Start Date: | February 4, 2019 |
| End Date: | April 29, 2019 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
Assessment of Regional Gastrointestinal Absorption of BMS-986165 Using Pharmacoscintigraphic Evaluation in Healthy Male Subjects
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
- Estimated glomerular filtration rate (eGFR) > 80 mL/min/1.732 calculated with the
Chronic Kidney Disease Epidemiology Collaboration formula
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study drug administration) disease of the gut
that, in the opinion of the Investigator or Medical Monitor, could impact upon the
absorption of study drug
- Acute diarrhea, or constipation within 3 weeks prior to randomization
- Any major surgery within 4 weeks of randomization
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
